Krystal Biotech (KRYS) Change in Accured Expenses (2016 - 2026)

Krystal Biotech has disclosed Change in Accured Expenses across 11 years of filings, most recently posting -$6.3 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$6.3 million, down 270.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 71.25% YoY), and the FY2025 annual result was $14.1 million, up 161.62% from the prior year.
• Change in Accured Expenses came in at -$6.3 million for Q1 2026 at Krystal Biotech, down from $5.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q4 2024 to a low of -$6.3 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $1.9 million (2024), against an average of $1.3 million.
• Across the five-year window, Change in Accured Expenses soared 629.35% in 2022 and sank 272.03% in 2023, its largest moves.
• Krystal Biotech's Change in Accured Expenses stood at $2.2 million in 2022, then soared by 70.75% to $3.7 million in 2023, then surged by 103.18% to $7.5 million in 2024, then retreated by 22.68% to $5.8 million in 2025, then sank by 209.09% to -$6.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.3 million (Q1 2026), $5.8 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.